In the EZH2 single agent–treated mice, tumor cells showed higher levels of H2-KdDd, which were reduced in the combination treated tumors potentially through targeting and clearance of MHC-high cells (Fig. 5F). This evidence concerns the gene EZH2 and neoplasm.